Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 12, 2024
Setrusumab receives Breakthrough Therapy designation from the FDA
Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027
Read more at globenewswire.com
